



RARE DISEASES MCDA criteria implementation results in European countries

Professor Olha Zalis'ka, PhD, DSci (Pharm.),

Head of Department of **Management&Economy of Pharmacy,
Drug Technology and Pharmacoconomics,**

Postgraduate Faculty,

Danylo Halytsky Lviv National Medical University,

Lviv, Ukraine

Founder &Past President ISPOR Ukraine Chapter,



20 th ISPOR European Congress

Glasgow, Scotland

04 November 2017

RARE diseases in Ukraine

- ▶ Law of Ukraine dated 15.04.2014 № 1213–VII
“About medical providing for rare diseases
and special products for patients “
- ▶ List of rare diseases included 171 disease
- ▶ Special government medical programs:
- ▶ Hemophilia
- ▶ Disease Hoshe
- ▶ Mucopolysaccharidosis



Strategy Ukraine –2020

- ▶ President Decree from 12 January 2015 № 5/2015 approved
- ▶ “Strategy of sustainable development «Ukraine–2020»

Main priorities:

- ▶ E–Patient registries
- ▶ improvement in public health
- ▶ family medicine,
- ▶ pharmaceutical care for in– and out patients

3

MCDA CRITERIA

- ▶ Severity
- ▶ Equity
- ▶ Patient Preference
- ▶ Safety
- ▶ Efficacy
- ▶ Strategic
- ▶ Budget Impact
- ▶ Unmet Need

Patient / drugs

Government

MCDA



Fig.1




Fig.2



Transferability and application in CEE countries

AGENDA

Moderator:

- ▶ **Olha Zaliska**, PhD, Dsi (Pharm.) Professor,
▶ Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

SPEAKERS:

- ▶ **John Yfantopoulos**, Professor, Health Economics, PhD,
President ISPOR Greece Chapter, University of Athens, Greece
- ▶ **Francesco Severio Mennini**, MSc, Professor of Health
Economics and Research Director, CEIS Economic Evaluation and
HTA (EEHTA), University Tor Vergata Roma, Rome, Italy
- ▶ **Taric Catic**, PhD (c) Health Economics and Pharmacoeconomics,
Consultant, Medical Manager, Novo Nordisk, Sarajevo, Bosnia
- ▶ **Rok Gren**, PhD, MSc., IHP (HE), President ISPOR Slovenia Chapter,
Assistant Professor, Institute of Mathematics, Physics and
Mechanics, Ljubljana, Slovenia

